This is the authors' abstract. We don't add key points for this paper.
Vaccine responses decline with age, yet the underlying mechanisms remain unclear. Using an aluminum hydroxide (Alum)-adjuvanted spike (S+Alum) vaccine, this study identifies an aging-linked pathway in which senescence-associated secretory phenotype (SASP) cytokines (C-C motif chemokine ligand 2, interleukin [IL]-6, and interferon-γ) at the injection site are upregulated and associate with increased histocompatibility 2, T region locus 23 ( H2-T23 ; Qa-1 b ) expression on monocytes. These H2-T23 high monocytes interact with MHCII high conventional type 2 dendritic cells via IL-10/transforming growth factor β, limiting dendritic cell antigen presentation, and engage the CD94/natural killer cell receptor group II number A (NKG2A)-Qa-1 b checkpoint on T cells, further dampening immunity. In humans, HLA-E + monocytes and NKG2A + T cells are infrequent in young individuals but show higher prevalence in peripheral blood from older adults, highlighting this pathway as a regulatory target. Blocking the CD94/NKG2A-Qa-1 b axis thus emerges as a potential strategy to enhance vaccine performance in aging populations. Overall, the findings define a mechanistic link between SASP-driven myeloid programming, impaired antigen presentation, and checkpoint-mediated T cell restraint in aging, with implications for vaccine design tailored to older individuals.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: